Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31559177 | 0.90 | MCL1 (0.49) | L3MBTL1IP6K1KDM4EACVR1MCL1 | |
| SCHEMBL1500289 | 0.86 | L3MBTL1 (0.48) | L3MBTL1IP6K1KDM4EACVR1MCL1 | |
| SCHEMBL7600132 | 0.81 | L3MBTL1 (0.60) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL29607244 | 0.81 | L3MBTL1 (0.60) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL12963735 | 0.80 | LMNA (0.61) | MCL1ALDH1A1HPGDLMNAHTT | |
| SCHEMBL9919060 | 0.79 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL30898575 | 0.79 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL3230513 | 0.79 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 | |
| SCHEMBL3751890 | 0.79 | CHEK1 (0.51) | MCL1ALDH1A1LMNACHEK1PIM1 | |
| SCHEMBL31723363 | 0.79 | L3MBTL1 (0.59) | L3MBTL1IP6K1KDM4EACVR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665330-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025090514-A1 | COVALENT SARM1 INHIBITORS | NURA BIO, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4073044-B1 | NEW BRAF INHIBITORS AS PARADOX BREAKERS | HOFFMANN LA ROCHE (CH) | 2025-02-19 | — | — | EP | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| WO-2024173196-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024151741-A1 | MUTANT-SELECTIVE EGFR INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-114746405-B | Novel BRAF inhibitors as anomalous breakers | 豪夫迈·罗氏有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-114989173-B | Imidazole compound, pharmaceutical composition and application thereof | 广州市恒诺康医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023183470-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-2007736-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | AstraZeneca AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2007113557-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113558-A2 | QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1789399-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | L3MBTL1 2538/4885IP6K1 151/4885KDM4E 2695/4885 |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | L3MBTL1 3635/4885IP6K1 1018/4885KDM4E 2090/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | L3MBTL1 1278/4885IP6K1 870/4885KDM4E 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.